Skip to main content

Table 1 Outline of planned treatment interventions by visit

From: Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial

  Rituximab group Cyclophosphamide group
Day 0 IV active rituximab 1000 mg IV 600 mg mg/m2 body surface area
Day 14 IV active rituximab 1000 mg Placebo
Week 4 Placebo IV 600 mg mg/m2 body surface area
Week 8 Placebo IV 600 mg mg/m2 body surface area
Week 12 Placebo IV 600 mg mg/m2 body surface area
Week 16 Placebo IV 600 mg mg/m2 body surface area
Week 20 Placebo IV 600 mg mg/m2 body surface area
  1. IV intravenously administered